DiaSorin (OTCMKTS:DSRLF) Shares Gap Down - Time to Sell?

Key Points

• DiaSorin gapped down pre-market from $70.76 to $67.00 on Monday with only 100 shares trading, and the stock is trading well below its 50‑day ($80.48) and 200‑day ($81.62) moving averages, indicating negative technical momentum.
• Analyst coverage is mixed — two Buy and two Hold ratings yield an average rating of "Moderate Buy"; recent notes include Deutsche Bank reiterating a Hold and BNP Paribas Exane upgrading to Neutral.
• DiaSorin S.p.A. is an Italy‑based immunodiagnostics and molecular diagnostics company that trades in the U.S. OTC market as DSRLF, a factor investors should weigh for liquidity and cross‑market considerations.

DiaSorin S.p.A. (OTCMKTS:DSRLF - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $70.76, but opened at $67.00. DiaSorin shares last traded at $67.00, with a volume of 100 shares trading hands.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of DiaSorin in a research report on Tuesday, February 10th. BNP Paribas Exane upgraded DiaSorin to a "neutral" rating in a research note on Wednesday, January 28th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, DiaSorin has an average rating of "Moderate Buy".

DiaSorin Stock Performance

The business's 50-day moving average is $80.48 and its two-hundred day moving average is $81.62.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company's shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin's business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.